In the last year, Cibus Global generated $2.3 million in revenue and had a net loss of $23.9 million.
Morgan Stanley, BofA Merrill Lynch and Piper Jaffray acted as the underwriters for the IPO.
Cibus Global provided the following description of their company for its IPO: ” We are a biotechnology company using advanced technologies to develop desirable plant traits for the global seed industry. Founded in 2001, we have developed and are commercializing a proprietary and highly differentiated gene-editing technology, which we refer to as the Rapid Trait Development System. RTDS enables us to efficiently introduce customizable, specific and predictable value-enhancing traits into plants and microorganisms. This ability to precisely edit plant genes without the integration of foreign genetic material, or recombinant DNA, establishes our technology as truly non-transgenic, both in process and product, and distinguishes us from competitors. “.
Cibus Global was founded in 2001 and has 134 employees. The company is located at 6455 Nancy Ridge Drive, San Diego, CA 92121, US and can be reached via phone at +1 (858) 450-0008 or on the web at http://www.cibus.com.
Receive News & Ratings for Cibus Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cibus Global and related companies with MarketBeat.com's FREE daily email newsletter.